GlucoTrack, Inc. (NASDAQ:GCTK) Short Interest Update

GlucoTrack, Inc. (NASDAQ:GCTK) saw a large increase in short interest in the month of September. As of September 15th, there was short interest totaling 96,610 shares, an increase of 287.2% from the August 31st total of 24,951 shares. Based on an average trading volume of 128,278 shares, the short-interest ratio is presently 0.8 days. Currently, 14.5% of the shares of the company are short sold.

GlucoTrack Price Performance

Shares of NASDAQ GCTK traded down $0.76 during mid-day trading on Friday, reaching $1.82. The company’s stock had a trading volume of 1,986,581 shares, compared to its average volume of 4,076,432. The company has a debt-to-equity ratio of 0.08, a current ratio of 0.46 and a quick ratio of 0.46. GlucoTrack has a 52 week low of $1.77 and a 52 week high of $136.29. The stock has a fifty day moving average of $4.54 and a two-hundred day moving average of $8.23. The firm has a market capitalization of $1.28 million, a PE ratio of -0.01 and a beta of 0.62.

Analyst Ratings Changes

A number of equities analysts have weighed in on GCTK shares. Weiss Ratings reiterated a “sell (e+)” rating on shares of GlucoTrack in a research report on Friday, July 17th. Wall Street Zen upgraded shares of GlucoTrack from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 8th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company presently has a consensus rating of “Sell”.

GlucoTrack News Roundup

Here are the key news stories impacting GlucoTrack this week:

• Positive Sentiment: Lōkahi Therapeutics expanded its ai² PIPELINE™ program through a collaboration with Pepperdine E2B™. The partnership could support development of Lōkahi’s AI-driven asset platform and strengthen the subsidiary’s potential to generate fee-based revenue. Lōkahi Therapeutics expands ai2 Pipeline through collaboration with Pepperdine E2B
• Positive Sentiment: The earlier announcement that Lōkahi signed its first external, fee-for-service partnership triggered a major rally in GCTK shares. Investors viewed the agreement as an initial commercial validation of the ai² PIPELINE platform and Lōkahi’s strategy to turn internal development capabilities into a revenue-generating business. Why GlucoTrack shares traded higher
• Neutral Sentiment: Reported short interest rose sharply to 96,610 shares as of September 15, equal to about 14.5% of shares outstanding. This indicates elevated bearish positioning, but the short-interest ratio of less than one day also suggests limited days-to-cover risk. A separate report showing zero short interest appears inconsistent and may reflect a data error.
• Negative Sentiment: GlucoTrack priced a public offering expected to raise roughly $3 million, or approximately $3.1 million before expenses, at $2.04 per share. The financing provides cash for operations and development but creates dilution and was priced below levels reached during the Lōkahi-related rally, likely contributing to the recent decline. GlucoTrack prices public offering

GlucoTrack Company Profile

GlucoTrack, Inc is a medical device company focused on developing glucose-monitoring technologies for people with diabetes. Its work is aimed at providing alternatives to conventional finger-stick testing and other invasive methods used to measure blood glucose.

The company’s earlier flagship product, GlucoTrack, was designed as a noninvasive glucose monitor that used a combination of ultrasonic, electromagnetic and thermal technologies to estimate glucose levels through the earlobe. GlucoTrack has also shifted its development focus toward an implantable continuous blood glucose monitoring system intended to provide ongoing glucose measurements over an extended period.

Historically known as Integrity Applications, Inc, the company adopted the GlucoTrack name to reflect its focus on glucose-monitoring technology.